Concentrations of S100B and neurofilament light chain in blood as biomarkers for checkpoint inhibitor–induced CNS inflammation-Reference-Cited by-同舟云学术

Concentrations of S100B and neurofilament light chain in blood as biomarkers for checkpoint inhibitor–induced CNS inflammation

Published:2024-02 Issue: Volume:100 Page:104955
ISSN:2352-3964
Container-title:eBioMedicine
language:en
Short-container-title:eBioMedicine

Author:

Bjursten Sara^ORCID,Zhao Zhiyuan,Al Remawi Hifaa,Studahl Marie,Pandita Ankur,Simrén Joel,Zetterberg Henrik,Lundell Anna-Carin,Rudin Anna,Ny Lars,Levin Max

Publisher

Elsevier BV

Reference52 articles.

1. Five-Year survival with combined nivolumab and ipilimumab in advanced melanoma;Larkin;N Engl J Med,2019

2. Nivolumab plus ipilimumab in advanced Non-small-cell lung cancer;Hellmann;N Engl J Med,2019

3. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial;Albiges;ESMO Open,2020

4. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Haanen;Ann Oncol,2018

5. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline;Brahmer;J Clin Oncol,2018

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diagnostic and prognostic biomarkers in immune checkpoint inhibitor-related encephalitis: a retrospective cohort study;The Lancet Regional Health - Europe;2024-09

2. Cavitation in blunt impact traumatic brain injury;Experiments in Fluids;2024-07-17

3. Bibliometric analysis of neuroinflammation and Alzheimer’s disease;Frontiers in Aging Neuroscience;2024-07-15

4. Cerebral clues: serum neurofilament light chain (sNfL) as a novel biomarker for immune check point inhibitor (ICI) mediated seronegative encephalitis;Oxford Medical Case Reports;2024-06-01

5. Central nervous system adverse events of immune checkpoint inhibitors;Current Opinion in Neurology;2024-03-14